| |
[摘要]：Introduction: Aminopeptidase N (APN/CD13) acts as an exopeptidase and has been studied for decades. In recent years, it has been seen not only as a tumor-related target but also as a potential functional protein in various other physiological or pathological processes, such as analgesia, virus infection and inflammation.Areas covered: In this review, APN inhibitors in the patents publicized during 2006 - 2010 are introduced. Readers will gain information on the patent inhibitors, including chemical structures, original sources or synthetic methods, biological assays and application potential.Expert opinion: It is difficult to identify compounds that interact with the function not relevant with peptide-hydrolysis of APN in the enzyme activity assay, and such compounds have not been reported in the patents during the past 5 years. The progress of protein-small molecule interaction detecting means, such as surface plasmon resonance, will possibly help develop such compounds for the treatment of relevant diseases or new molecular probes in mechanism investigation. |
|
